Figure 2. ST1072 modulates B- and T-cell functions during cGVHD development.

BALB/c mice were lethally irradiated and 5×10⁶/mouse TCD-BM or plus 5×10⁶/mouse splenocytes from B10.D2 donor mice were transplanted. One group of the recipient mice was injected i.p. with ST1072 at 2 mg/kg from day-1 to day 28 or day 28 to day 59. The recipients were monitored for body weight and clinical score until 60 days post-BMT. 60 days post cell transfer, spleens and peripheral lymph nodes (pLNs) were collected from the recipient mice and subjected to cell counting and FACS staining. Percentage of CD4⁺ or CD8⁺ among donor cells and percentage of IFN-γ among CD4⁺ or CD8⁺ donor cells are shown in recipient spleens (A) or periphery lymph nodes (pLNs) (B). Percentages of B220⁺ or B220^lowCD138⁺ and FAS⁺GL⁺ (germinal center cell, GC cell) are shown among donor B cells in recipient spleens (C). Pooled data is summarized with statistical analyses where either treatment (day 0 or 28) was compared with vehicle control. Data shown is one of the two replicate experiments. Significance is determined by one-way ANOVA (using multiple comparison test). Asterisks indicate statistical significance *p< 0.05, **p < 0.01, ***p < 0.001.